Endovascular Revascularization for Chronic Carotid Artery Occlusion Trial (ERCAO)

National Taiwan University

Status: Enrolling

Conditions: Carotid Occlusion

Treatments: Device: Endovascular revascularization

Study type: Interventional

Funder types: Other

Identifiers

NCT03179774

201702049RINA

Details and patient eligibility

About

Revascularization for carotid artery occlusion (CAO) remained controversial, there is no prospective randomized control trial (RCT) regarding carotid artery stenting (CAS) in CAO patients. The investigators conduct a prospective study composed of clinical registry arm and RCT arm. The main purpose of the study is investigate neurocognitive function at 3 months and thereafter up to 12 months.

Full description

Carotid artery stenosis is an important cause of stroke. Carotid artery stenting (CAS) provides non-inferior clinical outcome comparing to carotid endarterectomy (CEA). However, revascularization for carotid artery occlusion (CAO) remained controversial, owing to failed extracranial-to-intracranial (EC-IC) artery bypass trials, anatomical hindrance for CEA, and technical limitation for CAS. In the past 10 years, the investigators devoted in endovascular therapy for CAO and published innovative and pilot study results regarding feasibility of CAS for CAO, neurocognitive function (NCF) improvement after successful CAS for CAO, and predictors for CAS success in CAO, all in high-ranking journals. Moreover, successful CAS for CAO would lead to lower mortality and stroke rate during long-term follow-up, according to the preliminary analysis from the investigators. However, there is no prospective randomized control trial (RCT) regarding CAS in CAO patients, and in fact, most of the CAS trials excluded CAO.

The investigators, with the largest volume and experience in CAO recanalization in the world, felt obliged and responsible to propose the following RCT to evaluate endovascular revascularization for chronic CAO.

The study composed of two parts. The first part composed of prospective clinical registry for CAO. The second part compose of a prospective superiority trial, rater blinded, with 1:1 randomization to evaluate the clinical efficacy of interventional therapy for CAO. Eligible candidates for CAO revealed by CT, ultrasonography, angiography, or magnetic resonance imaging (MRI), with abnormal brain perfusion demonstrated by CT perfusion study (CTP) or MRI, will be enrolled in to study. If the participants agreed for randomization, participants will be randomized into 2 groups: the optimal medical therapy (OMT) group and the endovascular revascularization plus optimal medical therapy (ER+OMT) group. The primary end-point of the trial is the NCF improvement at 3 months and thereafter up to 12 months. The secondary endpoint includes: cumulative incidence of death and stroke within 30 days after the procedure; death or ipsilateral stroke between 31 days and 1 year; major stroke, ischemic stroke, or hemorrhagic stroke within 30 days after the procedure; major stroke, ischemic stroke, or hemorrhagic stroke between 31 days and 1 year; cognitive function measured by CANTAB; change of cerebral perfusion measured by CTP; target vessel revascularization rate; technique success rate; procedure success rate; and major procedure complication.

Enrollment: 200 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Part 1: Clinical registry study

Inclusion criteria for clinical registry study

• Patient age 20 years or older
• Abnormal cerebral perfusion by CTP or MRI
• No medical history of stroke or transient ischemic attack (TIA) ipsilateral to the carotid occlusion within 90 days of randomization
• Women must not be of childbearing potential or, if of childbearing potential, have a negative pregnancy test prior to randomization.

Exclusion Criteria for clinical registry study

• Patient has acute stroke within 90 days,
• Intolerance or allergic reaction to a study medication without a suitable management alternative.
• Patient is expected to have the ADP antagonist therapy interruption within 3 months after the procedure.
• GI hemorrhage within 1 month prior to enrollment that would preclude antiplatelet therapy
• Bleeding diathesis
• Intracranial hemorrhage within the past 12 months.
• Platelet count <100,000/μl or history of heparin-induced thrombocytopenia.
• Other high-risk cardiac sources of emboli, including left ventricular aneurysm, severe cardiomyopathy, aortic or mitral mechanical heart valve, severe calcific aortic stenosis (valve area < 1.0 cm2), endocarditis, moderate to severe mitral stenosis, left atrial thrombus, or any intracardiac mass, or known unrepaired patent foramen ovale (PFO) with prior paradoxical embolism.
• Any major surgery, major trauma, revascularization procedure within the past 1 month.
• Acute coronary syndrome within the past 1 month or acute coronary syndrome (ACS) that is not amenable to revascularization (patients should undergo planned coronary revascularization at least 30 days before randomization).
• Inability to understand and cooperate with study procedures or provide informed consent.
• Patients with < 5 years life expectancy
• Concomitant vascular conditions precluding endovascular revascularization procedure;
• Previous ipsilateral carotid artery stenting
• Intracranial aneurysm or arteriovenous malformation;
• Educational level lower than elementary school;
• Aphasia or right-sided hemiparesis
• Marked depression.
• Severe dementia.

Part 2: Randomized control study

Inclusion Criteria for randomized control study

• Patient age 20 years or older
• Abnormal cerebral perfusion by CTP or MRI
• No medical history of stroke or TIA ipsilateral to the carotid occlusion within 90 days of randomization
• Patients must have a modified Rankin Scale (mRS) ≤2 at the time of informed consent.
• Women must not be of childbearing potential or, if of childbearing potential, have a negative pregnancy test prior to randomization.
• Randomization will apply to only 1 carotid artery occlusion for patients with bilateral carotid occlusion. Intervention of the contralateral stenosis, should it exists, may be done in according to clinical indications at least 30 days prior to randomization.

Exclusion Criteria randomized control study

• Patient has acute stroke within 90 days,
• Prior major ipsilateral stroke in the past with moderate disability (mRS ≥ 3) that is likely to confound study outcomes.
• Current neurologic illness characterized by fleeting or fixed neurologic deficits that cannot be distinguished from TIA or stroke.
• Patient has significant renal insufficiency with estimated glomerular filtration rate (eGFR) <30 ml/min (at screening). and would not receive renal replacement therapy if contrast agent related nephropathy occurs
• Intolerance or allergic reaction to a study medication without a suitable management alternative.
• Patient is expected to have the ADP antagonist therapy interruption within 3 months after the procedure.
• GI hemorrhage within 1 month prior to enrollment that would preclude antiplatelet therapy
• Bleeding diathesis
• Intracranial hemorrhage within the past 12 months.
• Platelet count <100,000/μl or history of heparin-induced thrombocytopenia.
• Other high-risk cardiac sources of emboli, including left ventricular aneurysm, severe cardiomyopathy, aortic or mitral mechanical heart valve, severe calcific aortic stenosis (valve area < 1.0 cm2), endocarditis, moderate to severe mitral stenosis, left atrial thrombus, or any intracardiac mass, or known unrepaired PFO with prior paradoxical embolism.
• Major (non-carotid) surgery/procedures planned within 3 months after enrollment.
• Any major surgery, major trauma, revascularization procedure within the past 1 month.
• Acute coronary syndrome within the past 1 month or ACS that is not amenable to revascularization (patients should undergo planned coronary revascularization at least 30 days before randomization).
• Coronary artery disease with two or more proximal or major diseased coronary arteries with ≥ 70% stenosis that have not, or cannot, be revascularized.
• Inability to understand and cooperate with study procedures or provide informed consent.
• Patients with < 5 years life expectancy
• Concomitant vascular conditions precluding endovascular revascularization procedure;
• Previous ipsilateral carotid artery stenting
• Intracranial aneurysm or arteriovenous malformation;
• Educational level lower than elementary school;
• Aphasia or right-sided hemiparesis
• Marked depression.
• Severe dementia.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 4 patient groups

Clinical registry-ER and OMT

Experimental group

Description:

In clinical registry setting, participants who selected Endovascular revascularization and optimal medical therapy as the treatment for carotid artery occlusion are enrolled.

Treatment:

Device: Endovascular revascularization

Clinical registry-OMT

No Intervention group

Description:

In clinical registry setting, participants who selected optimal medical therapy as the treatment for carotid artery occlusion are enrolled.

RCT-ER and OMT

Experimental group

Description:

In randomized control trial setting, participants who are randomized to received endovascular revascularization and optimal medical therapy for carotid artery occlusion are enrolled.

Treatment:

Device: Endovascular revascularization

RCT-OMT

No Intervention group

Description:

In randomized control trial setting, participants who are randomized to received optimal medical therapy for carotid artery occlusion are enrolled.